Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02583165 · ClinicalTrials.gov registry record · Phase 1

A Study in Adult Subjects With Select Advanced Solid Tumors

A Phase 1 study, sponsored by MedImmune.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT02583165: Completed Phase 1 study, sponsored by MedImmune.

NCT02583165 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02583165, a Phase 1 study, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

To evaluate the safety and tolerability of MEDI1873 in adult subjects with selected advanced solid tumors.

Primary Outcome

The maximum tolerated dose (MTD)/highest protocol-defined dose level in the absence of establishing an MTD will be determined by the number of participants experiencing DLTs. The safety profile will be assessed through number of participants experiencing AEs, SAEs, DLTs, abnormal laboratory parameters, vital signs and electrocardiogram (ECG) results.

Interventions

  • BIOLOGICAL MEDI1873

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2015-11-09
Est. Completion 2018-12-19
Phase Phase 1
MedImmune

210 total trials

What the finished NCT02583165 record still lists

NCT02583165 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 1 intervention - of which MEDI1873 is the first listed.

NCT02583165 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02583165 about?

NCT02583165 is a clinical study titled "A Study in Adult Subjects With Select Advanced Solid Tumors". To evaluate the safety and tolerability of MEDI1873 in adult subjects with selected advanced solid tumors.

What is the current status of trial NCT02583165?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-11-09. Estimated completion is 2018-12-19.

What interventions are being tested in trial NCT02583165?

The interventions under investigation include: MEDI1873 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02583165?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02583165's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02583165, the US trial registry maintained by the National Library of Medicine. NCT02583165 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.